Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI362 vs Semaglutide in Early Type 2 Diabetes and Obesity (DREAMS-3)
NCT06184568Phase 3Completed
- Sponsor
- Innovent Biologics
- Start
- Feb 2024
- Primary completion
- Sep 2025
- Modality
- Hormonal Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of mazdutide in type 2 diabetes mellitus (T2DM), obesity, sponsored by Innovent Biologics. Started Feb 2024; status: completed.
02
Drugs
mazdutide
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06184568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06184568.